CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows From Operating Activities:
Net income	$ 11,216	$ 39,655
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	3,891	1,779
Realized gain on marketable securities	0	(107)
Gain upon divestiture of assets to Turing Pharmaceuticals	0	(914)
Deferred income tax benefit	(5,070)	(40,021)
Interest income from notes receivable	(640)	0
Non-cash interest expense	532	499
Amortization of premiums on marketable securities	389	0
Amortization of debt discount and deferred financing costs	163	502
Lease liability	0	(160)
Legal accrual reversal	(2,967)	0
Bargain purchase gain	0	(48,578)
Share based compensation	6,793	5,573
Derivative financial instruments, warrants, issued, recorded in interest expense	0	1,050
Change in estimated fair value of liability classified warrants	(14,340)	36,753
Change in estimated fair value of contingent consideration	2,695	0
Payments related to change in fair value of contingent consideration	(427)	(90)
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(927)	(203)
Inventory	(302)	(353)
Prepaid expenses and other current assets	(1,013)	127
Accounts payable and accrued expenses	(3,560)	(2,106)
Net cash used in operating activities	(3,567)	(6,594)
Cash Flows From Investing Activities:
Purchase of fixed assets	(24)	(25)
Cash paid for intangible assets	(2,575)	(948)
Proceeds from the sale/maturity of marketable securities	17,495	282
Purchase of marketable securities	(24,652)	0
Cash received upon divestiture of asset	0	3,311
Cash paid upon acquisition, net of cash acquired	0	(33,430)
Net cash used in investing activities	(9,756)	(30,810)
Cash Flows From Financing Activities:
Payment of guaranteed minimum royalty	(500)	(500)
Proceeds from exercise of warrants	0	520
Payment of other liability	0	(500)
Proceeds from exercise of stock options	781	157
Proceeds received from issuance of common stock	0	149,454
Financing costs from issuance of common stock	0	(9,201)
Net cash used in (provided by) financing activities	(926)	139,375
Effect of exchange rate changes on cash	(294)	0
Net change in cash	(14,543)	101,971
Cash, beginning of year	37,805	18,204
Cash, end of period	23,262	120,175
Manchester
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	(992)	(555)
Asklepion
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	$ (215)	$ 0